Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118048714> ?p ?o ?g. }
- W2118048714 endingPage "1184" @default.
- W2118048714 startingPage "1174" @default.
- W2118048714 abstract "RIPK2 mediates pro-inflammatory signaling from the bacterial sensors NOD1 and NOD2, and is an emerging therapeutic target in autoimmune and inflammatory diseases. We observed that cellular RIPK2 can be potently inhibited by type II inhibitors that displace the kinase activation segment, whereas ATP-competitive type I inhibition was only poorly effective. The most potent RIPK2 inhibitors were the US Food and Drug Administration-approved drugs ponatinib and regorafenib. Their mechanism of action was independent of NOD2 interaction and involved loss of downstream kinase activation as evidenced by lack of RIPK2 autophosphorylation. Notably, these molecules also blocked RIPK2 ubiquitination and, consequently, inflammatory nuclear factor κB signaling. In monocytes, the inhibitors selectively blocked NOD-dependent tumor necrosis factor production without affecting lipopolysaccharide-dependent pathways. We also determined the first crystal structure of RIPK2 bound to ponatinib, and identified an allosteric site for inhibitor development. These results highlight the potential for type II inhibitors to treat indications of RIPK2 activation as well as inflammation-associated cancers." @default.
- W2118048714 created "2016-06-24" @default.
- W2118048714 creator A5009470126 @default.
- W2118048714 creator A5026464853 @default.
- W2118048714 creator A5028960316 @default.
- W2118048714 creator A5029510722 @default.
- W2118048714 creator A5033650842 @default.
- W2118048714 creator A5034426287 @default.
- W2118048714 creator A5055567926 @default.
- W2118048714 creator A5058652447 @default.
- W2118048714 creator A5058888670 @default.
- W2118048714 creator A5065441188 @default.
- W2118048714 creator A5069367568 @default.
- W2118048714 creator A5078336595 @default.
- W2118048714 creator A5078379938 @default.
- W2118048714 creator A5087815486 @default.
- W2118048714 date "2015-09-01" @default.
- W2118048714 modified "2023-09-30" @default.
- W2118048714 title "Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors" @default.
- W2118048714 cites W1492798098 @default.
- W2118048714 cites W1642457845 @default.
- W2118048714 cites W1670573097 @default.
- W2118048714 cites W1969756521 @default.
- W2118048714 cites W1970527727 @default.
- W2118048714 cites W1971046821 @default.
- W2118048714 cites W1976644844 @default.
- W2118048714 cites W1985831101 @default.
- W2118048714 cites W1989633650 @default.
- W2118048714 cites W1992013566 @default.
- W2118048714 cites W1992219661 @default.
- W2118048714 cites W1992693390 @default.
- W2118048714 cites W1993675254 @default.
- W2118048714 cites W1996148181 @default.
- W2118048714 cites W2000106654 @default.
- W2118048714 cites W2001166572 @default.
- W2118048714 cites W2002972295 @default.
- W2118048714 cites W2009755744 @default.
- W2118048714 cites W2014167332 @default.
- W2118048714 cites W2029397486 @default.
- W2118048714 cites W2040024879 @default.
- W2118048714 cites W2042328112 @default.
- W2118048714 cites W2049140335 @default.
- W2118048714 cites W2049587638 @default.
- W2118048714 cites W2054525360 @default.
- W2118048714 cites W2055063967 @default.
- W2118048714 cites W2064512811 @default.
- W2118048714 cites W2071855846 @default.
- W2118048714 cites W2075583035 @default.
- W2118048714 cites W2077511764 @default.
- W2118048714 cites W2079633740 @default.
- W2118048714 cites W2086607027 @default.
- W2118048714 cites W2089403477 @default.
- W2118048714 cites W2099259685 @default.
- W2118048714 cites W2111900042 @default.
- W2118048714 cites W2119502087 @default.
- W2118048714 cites W2119803499 @default.
- W2118048714 cites W2125185693 @default.
- W2118048714 cites W2125309974 @default.
- W2118048714 cites W2125763124 @default.
- W2118048714 cites W2127204501 @default.
- W2118048714 cites W2131729327 @default.
- W2118048714 cites W2136736147 @default.
- W2118048714 cites W2137218119 @default.
- W2118048714 cites W2139622747 @default.
- W2118048714 cites W2143625465 @default.
- W2118048714 cites W2143841612 @default.
- W2118048714 cites W2147109509 @default.
- W2118048714 cites W2153019398 @default.
- W2118048714 cites W2156163936 @default.
- W2118048714 cites W2156373035 @default.
- W2118048714 cites W2163498571 @default.
- W2118048714 cites W2164251428 @default.
- W2118048714 cites W2167617907 @default.
- W2118048714 doi "https://doi.org/10.1016/j.chembiol.2015.07.017" @default.
- W2118048714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4579271" @default.
- W2118048714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26320862" @default.
- W2118048714 hasPublicationYear "2015" @default.
- W2118048714 type Work @default.
- W2118048714 sameAs 2118048714 @default.
- W2118048714 citedByCount "95" @default.
- W2118048714 countsByYear W21180487142016 @default.
- W2118048714 countsByYear W21180487142017 @default.
- W2118048714 countsByYear W21180487142018 @default.
- W2118048714 countsByYear W21180487142019 @default.
- W2118048714 countsByYear W21180487142020 @default.
- W2118048714 countsByYear W21180487142021 @default.
- W2118048714 countsByYear W21180487142022 @default.
- W2118048714 countsByYear W21180487142023 @default.
- W2118048714 crossrefType "journal-article" @default.
- W2118048714 hasAuthorship W2118048714A5009470126 @default.
- W2118048714 hasAuthorship W2118048714A5026464853 @default.
- W2118048714 hasAuthorship W2118048714A5028960316 @default.
- W2118048714 hasAuthorship W2118048714A5029510722 @default.
- W2118048714 hasAuthorship W2118048714A5033650842 @default.
- W2118048714 hasAuthorship W2118048714A5034426287 @default.
- W2118048714 hasAuthorship W2118048714A5055567926 @default.
- W2118048714 hasAuthorship W2118048714A5058652447 @default.
- W2118048714 hasAuthorship W2118048714A5058888670 @default.